lower [2%:<2% to 3%), inflammation at injection site ( 2%) Miscellaneous: Postoperative pain (5%)> <2% (Limited to important or life-threatening): Abdominal swelling, albuminuria, back pain, breast pain, cardiac arrhythmia, cervical carcinoma, cervical lesion, cough, diarrhea, dizziness, dysuria, ectopic pregnancy, emotional lability, fever, flatulence, headache, heart murmur, herpes genitalis, hiccups, hot flash, hyperglycemia, hypersensitivity reaction, insomnia, intermenstrual bleeding, leukocytosis, leukorrhea, malaise, mastalgia, paresthesia, pharyngitis, pruritus, skin rash, upper respiratory tract infection, urinary incontinence, urinary tract infection, vaginal discomfort, vaginal hemorrhage, vaginitis, vulvovaginal candidiasis Warnings/Precautions Concerns related to adverse effects: Ovarian enlargement: May be accompanied by abdominal distention or abdominal pain and generally regresses without treatment within 2 to 3 weeks. If ovaries are abnormally enlarged on the last day of treatment, withhold hCG to reduce the risk of ovarian hyperstimulation syndrome (OHSS). Ovarian hyperstimulation syndrome: Ovarian hyperstimulation syndrome (OHSS) is a rare exaggerated response to ovulation induction therapy (Corbett 2014; Fiedler 2012). This syndrome may begin within 24 hours of treatment but may become most severe 7 to 10 days after therapy (Corbett 2014). Symptoms of mild/moderate OHSS may include abdominal distention/discomfort, diarrhea, nausea, and/or vomiting. Severe OHSS symptoms may include severe abdominal pain, anuria/oliguria, ascites, severe dyspnea, hypotension, or nausea/vomiting (intractable). Decreased creatinine clearance, hemoconcentration, hypoproteinemia, elevated liver enzymes, elevated WBC, and electrolyte imbalances may also be present (ASRM 2016; Corbett 2014; Fiedler 2012). Treatment is primarily symptomatic and includes fluid and electrolyte management, analgesics, and prevention of thromboembolic complications (ASRM 2016; SOGC-CFAS 2011). Therapy with gonadotropins should be stopped. Thromboembolism: In association with and separate from ovarian hyperstimulation syndrome (OHSS), arterial thromboembolic events have been reported. Special populations: Elderly: Safety and efficacy have not been established in the elderly. Pediatric: Safety and efficacy have not been established in children. Other warnings/precautions: Experienced physician: These medications should only be used by physicians who are thoroughly familiar with infertility problems and their management. Multiple births: May result from the use of these medications; advise patients of the potential risk of multiple births before starting the treatment. Monitoring Parameters Ultrasound and/or estradiol levels to assess follicle development; ultrasound to assess number and size of follicles; ovulation (basal body temperature, serum progestin level, menstruation, sonography) OHSS: Monitoring of hospitalized patients should include abdominal circumference, albumin, cardiorespiratory status, electrolytes, fluid balance, hematocrit, hemoglobin, serum creatinine, urine output, urine specific gravity, vital signs, weight (all daily or as necessary) and liver enzymes (weekly) (SOGC-CFAS 2011) Pregnancy Risk Factor X Pregnancy Considerations Adverse events were observed in animal reproduction studies. Ectopic pregnancy, premature labor, postpartum fever, and spontaneous abortion have been reported in clinical trials. Congenital abnormalities have also been observed, however, the incidence is similar during natural conception. Patient Education Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?) Patient may experience injection site irritation. Have patient report immediately to prescriber signs of severe cerebrovascular disease (change in strength on one side is greater than the other, difficulty speaking or thinking, change in balance, or vision changes), signs of DVT (edema, warmth, numbness, change in color, or pain in the extremities), breast pain, angina, vomiting blood, or signs of ovarian hyperstimulation syndrome (severe abdominal pain or bloating; severe nausea, vomiting, or diarrhea; excessive weight gain; shortness of breath; or change in amount of urine passed) (HCAHPS). Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions. Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients. Next Interactions Print this page Add to My Med List More about chorionic gonadotropin (hcg) Side Effects During Pregnancy Dosage Information Drug Interactions Support Group Pricing & Coupons En Español 15 Reviews Add your own review/rating Drug class: gonadotropins Consumer resources Human chorionic gonadotropin (HCG) injectable ... +3 more Professional resources Choriogonadotropin Alfa (AHFS Monograph) Gonadotropin, Chorionic (AHFS Monograph) Chorionic Gonadotropin (FDA) Chorionic Gonadotropin (Human) (Wolters Kluwer) Human Chorionic Gonadotropin (Advanced Reading) Other brands: Pregnyl , Ovidrel , Novarel Related treatment guides Obesity Female Infertility Hypogonadism, Male Ovulation Induction Prepubertal Cryptorchidism> ] Drug Status Rx Availability Prescription only X Pregnancy Category Not for use in pregnancy N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Chorionic gonadotropin (hcg) Rating 15 User Reviews 6.9 /10 15 User Reviews 6.9 Rate it! Manufacturer Fresenius Kabi USA, LLC Drug Class Gonadotropins Related Drugs gonadotropins HCG , Menopur , Pregnyl , Ovidrel , chorionic gonadotropin (hcg) , Novarel Hypogonadism, Male testosterone , AndroGel , Depo-Testosterone , Axiron , Androderm , Testim , More... Ovulation Induction Clomid , clomiphene , HCG , Menopur , Pregnyl , Ovidrel , More... Female Infertility Clomid , clomiphene , HCG , Menopur , Pregnyl , Ovidrel , More... 1 more conditions... you need to be
springing up Chorionic Gonadotropin (Recombinant) on occasion
EmoticonEmoticon